The drug diversion software market does not shift often, but when it does, healthcare organizations feel it quickly.
For teams now reevaluating vendors after the Bluesight acquisition of Protenus, this is a good time to review the broader market before signing anything new. → Compare Drug Diversion Software Options
That is exactly what Terri Vidals highlighted in her recent Diversion Insights episode discussing Bluesight’s acquisition of Protenus, a deal announced on January 9, 2025. Bluesight said the acquisition would strengthen its diversion platform and add Protenus’ patient privacy monitoring capabilities to its broader compliance offering.
What makes this story important is not just the acquisition itself. It is what happened next.
According to Terri, many former Protenus customers were not unhappy with their existing software at all. In her words, there are customers who were “very satisfied with Protenus, satisfied with the software itself, and certainly satisfied with the price point.”
A market shift that created immediate pressure
Bluesight’s stated strategy was clear: bring together diversion monitoring and patient privacy monitoring in a stronger, more unified compliance platform. That may make strategic sense at the enterprise level. But for hospitals and health systems that had chosen Protenus partly because it was more economical, the transition appears to be creating real friction.
Terri described the customer sentiment as “a little bit of consternation actually about this acquisition.”
That frustration is understandable.
When a healthcare organization chooses diversion software, the decision usually reflects more than feature lists. It also reflects staffing realities, reporting needs, data review capacity, implementation burden, and price tolerance. If a customer believed Protenus was already doing “the job that it needed,” a forced move to a higher-priced environment can feel less like an upgrade and more like a disruption.
Why former Protenus customers are re-evaluating everything
The biggest issue Terri raises is not just higher cost. It is timing.
From what she is hearing, some former Protenus customers are being pushed to make decisions now, even if they believed they still had time left under prior agreements. That creates urgency where there may not have been any before. Instead of evaluating software on their own roadmap, these teams now have to evaluate vendors under pressure.
That changes buyer behavior.
Rather than automatically moving forward with a replacement contract, many organizations appear to be doing what any prudent compliance leader would do: stepping back and asking whether this is the right moment to reassess the whole market.
That matters because the drug diversion technology space has already been consolidating. Larger platforms are absorbing niche vendors, while hospitals are trying to determine whether they want an enterprise suite, a focused diversion tool, or a hybrid approach supported by outside expertise. RXpert’s own recent review of the market notes that consolidation has changed how hospitals compare software, support, and long-term flexibility. See our Drug Diversion Software Comparison or download the 2026 Drug Diversion Software Market Report for a side-by-side look at the landscape.
Sticker shock is only part of the story
Price matters, especially in a market where many compliance teams are asked to do more with limited staff and tighter budgets.
But cost alone is not the full issue.
A platform change also introduces questions like these:
- Will the new system fit our existing workflows?
- How much retraining will this require?
- Will our current investigations process change?
- Are we buying features we actually need?
- How will this affect false positives, reporting burden, and analyst time?
- What happens to historical data and internal benchmarks?
Those are the kinds of operational questions that often matter more than a polished demo.
This is one reason broader best-practice guidance matters so much. The ASHP Guidelines on Preventing Diversion of Controlled Substances emphasize that organizations need rigorous monitoring, surveillance, and multidisciplinary oversight rather than a software-only mindset. The Joint Commission has also stressed the importance of detecting diversion within the healthcare workforce, and the DEA Diversion Control Division remains a core federal resource on diversion oversight.
In other words, choosing a vendor is only one part of building a defensible diversion mitigation strategy.
This may create opportunity for other vendors
One of Terri’s most useful observations is that this transition may create a real opening across the market.
If former Protenus customers are now being compelled to review new contracts anyway, many will naturally ask: why stop at one option?
That means more demos, more comparisons, and more scrutiny of how each platform handles:
- workflow blind spots,
- false positives,
- operating room visibility,
- investigation efficiency,
- reporting depth,
- and total cost of ownership.
For competing vendors, this is a chance to win business.
For buyers, it is a rare opportunity to pause and make a more strategic decision.
That does not mean every former Protenus customer should walk away from Bluesight. It means they should evaluate the situation carefully and make sure any decision is based on their real risk profile, not just on transition pressure.
What healthcare leaders should do before signing anything
If your organization is affected by this change, the smartest next step is not to rush. It is to assess your current diversion mitigation posture first.
Before committing to a new contract, ask:
- What gaps exist in our current monitoring program today?
- Which workflows are still not visible, regardless of software brand?
- How much analyst time are false positives costing us?
- Do we need software only, or do we also need outside program expertise?
- Are we comparing vendors based on features, or based on fit?
That last question is usually the most important.
A more expensive platform is not automatically a better platform for your organization. And a lower-cost platform is not always the most sustainable one either. The right answer depends on your staffing model, audit burden, internal expertise, and the maturity of your diversion mitigation program.
Start with a clear diversion risk picture.
If your organization hasn’t conducted a recent diversion risk review, now is the time.
→ Request a Free 30-Minute Drug Diversion Risk Assessment
Software alone will not solve the problem
The healthcare industry often talks about software selection as if it is the finish line.
It is not.
Even the best platform can underperform if an organization has weak policy alignment, incomplete data feeds, unclear investigation ownership, or inconsistent follow-through. That is why independent assessments remain so valuable during periods of market disruption.
At RXpert, we often see organizations focus heavily on the demo while overlooking the deeper question: Will this tool actually strengthen our diversion mitigation program in practice?
That is where independent support can make a difference.
Diversion often hides in complex medication data.
Advanced analytics can identify patterns that manual audits miss.
→ Explore RXpert Diversion Monitoring Services
Final takeaway
Terri’s podcast captured something important: this acquisition is not just a business headline. It is a real operational issue for healthcare organizations that suddenly find themselves reevaluating contracts, budgets, and software strategy all at once.
As she put it, “if you’re going to make me sign a new contract and pay these prices, then I’m going to do some shopping.”
That is a rational response.
For former Protenus customers, this moment is frustrating, but it is also clarifying. It creates a reason to step back, compare options carefully, and decide what kind of diversion monitoring approach best fits the organization going forward.
Every healthcare organization needs a clear diversion mitigation strategy.
Independent evaluations can identify monitoring gaps before they become compliance issues.
→ Get a Free 30 min Risk Assessment Today!
